Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Blood

• Publication date

  1992-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V80.5.1149.1149PMID 1515637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma

  2004cited by this paper
• Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma.

  1994cited by this paper
• Autologous bone marrow transplantation

  1993cited by this paper
• GM‐CSF as an adjunct to autologous bone marrow transplantation

  1993cited by this paper
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

  1992cited by this paper
• Feasibility of autologous bone marrow transplantation for early consolidation of follicular non‐Hodgkin's lymphoma

  1991cited by this paper
• GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.

  1991cited by this paper
• The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma.

  1991cited by this paper
• Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.

  1991cited by this paper
• Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

  1990cited by this paper
• Regeneration of granulopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor after bone marrow transplantation.

  1990cited by this paper
• Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.

  1990cited by this paper
• Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

  1990cited by this paper
• The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas.

  1990cited by this paper
• In vivo stimulation of megakaryocytopoiesis by recombinant murine granulocyte-macrophage colony-stimulating factor.

  1990cited by this paper
• Bone marrow transplantation in the treatment of patients with lymphoma.

  1989cited by this paper
• Autologous bone marrow transplants: Different indications in Europe and North America

  1989cited by this paper
• GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.

  1989cited by this paper
• In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.

  1989cited by this paper
• Interacting cytokines regulate in vitro human megakaryocytopoiesis.

  1989cited by this paper
• Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

  1988cited by this paper
• Analysis of early infectious complications after autologous bone marrow transplantation

  1988cited by this paper
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

  1988cited by this paper
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

  1988cited by this paper
• Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans.

  1988cited by this paper
• Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

  1987cited by this paper
• Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

  1987cited by this paper
• High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

  1987cited by this paper
• Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.

  1987cited by this paper
• Autologous bone-marrow transplantation.

  1987cited by this paper
• Recombinant murine granulocyte macrophage colony-stimulating factor has megakaryocyte colony-stimulating activity and augments megakaryocyte colony stimulation by interleukin 3.

  1987cited by this paper
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

  1987cited by this paper
• Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model.

  1987cited by this paper
• Evidence for direct action of human biosynthetic (recombinant) GM-CSF on erythroid progenitors in serum-free culture.

  1987cited by this paper
• The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow.

  1987cited by this paper
• Infection in bone marrow transplant recipients.

  1986cited by this paper
• Infectious complications in pediatric patients undergoing transplantation with T lymphocyte-depleted bone marrow.

  1986cited by this paper
• Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections.

  1986cited by this paper
• Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor.

  1985cited by this paper
• Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin.

  1985cited by this paper
• Granulocyte-macrophage colony-stimulating factors

  1985cited by this paper
• Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin.

  1985cited by this paper
• Granulocyte-macrophage colony-stimulating factors

  1985cited by this paper
• Autologous bone marrow transplantation in the treatment of poor prognosis non-Hodgkin's lymphomas.

  1984cited by this paper
• Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.

  1984cited by this paper
• Neutropenia, fever, and infection.

  1984cited by this paper
• Problems of infection after bone marrow transplantation.

  1983cited by this paper
• Infectious Complications of Human Bone Marrow Transplantation

  1979cited by this paper
• Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study.

  1977cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper
• National cancer institute sponsored study of classifications of non‐hodgkin's lymphomas. Summary and description of a working formulation for clinical usage

  year unknowncited by this paper

• Targeting the Spleen as an Alternative Site for Hematopoiesis

  2019cites this paper
• Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis

  2019cites this paper
• Adaptive Immunotherapy for Opportunistic Infections

  2019cites this paper
• Coencapsulation of insulin-producing cells and mesenchymal stromal cells in PEGDA hydrogels to enhance chronic wound healing

  2017cites this paper
• Granulopoiesis‐stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults

  2016cites this paper
• Granulocyte/macrophage colony-stimulating factor attenuates endothelial hyperpermeability after thermal injury.

  2015cites this paper
• [Idiopathic and secondary capillary leak syndromes: A systematic review of the literature].

  2015cites this paper
• Clinical application of growth factors and cytokines in wound healing

  2014cites this paper
• What's new in the literature: An update of new research since the original WHS diabetic foot ulcer guidelines in 2006

  2014cites this paper
• Granulocyte/Macrophage Colony-Stimulating Factor Influences Angiogenesis by Regulating the Coordinated Expression of VEGF and the Ang/Tie System

  2014cites this paper
• Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF)

  2012cites this paper
• Practice Guidelines for the Use of rHuG-CSF in an Oncology Setting

  2012cites this paper
• State-ofthe-Art Paper Vox Sanguinis

  2011cites this paper
• The myeloid growth factors.

  2011cites this paper
• High-dose chemotherapy and stem cell transplantation for advanced testicular cancer

  2011cites this paper
• SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

  2011cites this paper
• transplantation in mice and megakaryocytic reconstitution after syngeneic bone marrow Activated natural killer cells and interleukin-2 promote granulocytic

  2011cites this paper
• Topically applied rhGM-CSF for the wound healing: a systematic review.

  2011cites this paper
• Long‐term survival and late relapse in 2‐year survivors of autologous haematopoietic cell transplantation for Hodgkin and non‐Hodgkin lymphoma

  2009cites this paper
• Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection

  2007cites this paper
• Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.

  2006cites this paper
• Cytokines in hematopoietic stem cell transplantation.

  2005cites this paper
• Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

  2004cites this paper
• Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay

  2004cites this paper
• How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

  2004cites this paper
• Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer

  2004cites this paper
• Epidemiology of febrile neutropenia.

  2003cites this paper
• Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.

  2003cites this paper
• Current concepts in allogeneic hematopoietic stem cell transplantation.

  2003cites this paper
• GM-CSF — Biochemical purification and molecular and biologic characterization

  2003cites this paper
• Autologous and allogeneic transplantation for aggressive NHL.

  2002cites this paper
• Haemopoietic growth factors in paediatric oncology: a review of the literature.

  2001cites this paper
• Haemopoietic Growth Factors in Paediatric Oncology

  2001cites this paper
• Pleural effusion and pulmonary injury as an unusual complication to chemotherapy in non-small cell lung cancer patients.

  2000cites this paper
• The management of adult aggressive non-Hodgkin's lymphomas.

  2000cites this paper
• GM-CSF in haematopoietic stem cell transplantation.

  1999cites this paper
• Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?

  1999cites this paper
• The efficacy of recombinant tpo in murine and nonhuman primate models for myelosuppression and stem cell transplantation

  1998cites this paper
• Strategies for Prevention of Infection in Short-Duration Neutropenia

  1998cites this paper
• In Vitro And in Vivo Expansion of Stem Cell Populations

  1998cites this paper
• Haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cell rescue: the effects of the mobilization regimen and post-transplant growth factors.

  1998cites this paper
• Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer.

  1998cites this paper
• FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome

  1998cites this paper
• Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.

  1998cites this paper
• Hematopoietic growth factors in autologous transplantation

  1998cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF):Biology and Clinical Status

  1998cites this paper
• Haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cell rescue: the effects of the mobilization regimen and post-transplant growth factors.

  1998cites this paper
• The Efficacy of Recombinant Thrombopoietin in Murine and Nonhuman Primate Models for Radiation‐Induced Myelosuppression and Stem Cell Transplantation

  1998cites this paper
• Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint.

  1997cites this paper
• Advances in autologous stem cell transplantation.

  1997cites this paper
• Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.

  1997cites this paper
• Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantation.

  1997cites this paper
• Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia

  1997cites this paper
• rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial

  1997cites this paper
• The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation.

  1997cites this paper
• Expansion of Blood CD34+ Cells: Committed Precursor Expansion Does Not Affect Immature Hematopoietic Progenitors

  1997cites this paper
• Risk factors for capillary leakage syndrome after bone marrow transplantation

  1997cites this paper
• Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. American Society of Clinical Oncology/Eastern Co-operative Oncology Group.

  1997cites this paper
• Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count

  1997cites this paper
• The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.

  1997cites this paper
• The Efficacy of Single-Dose Administration of Thrombopoietin With Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys

  1997cites this paper
• Facteurs de croissance hématopoïetiques et tumeurs solides

  1997cites this paper
• Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.

  1997cites this paper
• Hematopoiesis: Clinical application of colony-stimulating factors

  1997cites this paper
• Initial Trial of PIXY 321 Following Autologous Bone Marrow Transplantation

  1997cites this paper
• Hematopoietic growth factors

  1996cites this paper
• Host immunologic augmentation for the control of infection.

  1996cites this paper
• Facteurs de croissance et infection

  1996cites this paper
• Cytokine Therapy After Bone Marrow Transplantation

  1996cites this paper
• Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.

  1996cites this paper
• Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

  1996cites this paper
• Economic Implications of High Dose Chemotherapy Programs with Autologous Stem Cell Support

  1996cites this paper
• High-dose chemotherapy in non-Hodgkin's lymphoma.

  1996cites this paper
• Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters

  1996cites this paper
• Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia.

  1996cites this paper
• Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?

  1996cites this paper
• Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.

  1996cites this paper
• Allogeneic bone marrow transplantation.

  1996cites this paper
• Chemotherapy and neutropenia.

  1996cites this paper
• A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.

  1996cites this paper
• An economic model to assess the savings from a clinical application of haematopoietic growth factors.

  1996cites this paper
• Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation.

  1996cites this paper
• Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.

  1996cites this paper
• Allogeneic marrow transplantation and the use of hematopoietic growth factors

  1995cites this paper
• High‐dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors

  1995cites this paper
• Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

  1995cites this paper
• Immunotherapy and immunoprophylaxis in bone marrow transplantation.

  1995cites this paper
• Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.

  1995cites this paper
• Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.

  1995cites this paper
• The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.

  1995cites this paper
• Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.

  1995cites this paper
• Granulocyte growth factors: achieving a consensus.

  1995cites this paper
• The role of hematopoietic growth factors in transfusion medicine.

  1995cites this paper
• Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity?

  1995cites this paper
• Colony-stimulating factors: current applications and perspectives.

  1995cites this paper
• Granulocyte‐macrophage colony‐stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trials

  1995cites this paper
• Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.

  1995cites this paper
• GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).

  1995cites this paper
• Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.

  1995cites this paper